A Phase Iii, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy And Safety Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Mild To Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Carriers
A Phase Iii, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy And Safety Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Mild To Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Carriers
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.
Inclusion Criteria:
Exclusion Criteria:
Springfield, Illinois 62702, United States
Columbs, Ohio 43210, United States
Columbs, Ohio 43210, United States
Charleston, South Carolina 29425, United States
Buenos Aires, Buenos Aires 1090, Argentina
West Heidelberg, Victoria 3081, Australia
Nantes - Saint Herblain, 44093, France
Gunma, 371-0014, Japan
Gunma, 371-8511, Japan
Gunma, 375-0017, Japan
Panorama, Western Cape 7500, South Africa
Thonex-Geneva, CH-1226, Switzerland